This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Development Remove Targeted Protein Degradation Remove Therapies
article thumbnail

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

JULY 22, 2021

The companies will equally share worldwide development costs, commercialization expenses, and profits. This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer.

Targeted Protein Degradation 52
Targeted Protein Degradation Therapies Clinical Trials Treatment 52
article thumbnail

Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. In this process, protein-degrading molecules ‘co-opt’ large cellular proteins (ubiquitin ligases) to breakdown other target proteins, including those that cause cancer. “We

Targeted Protein Degradation 40
Targeted Protein Degradation Small Molecule Clinical Development Disease 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 15,000+ Insiders by signing up for our newsletter

About
Webinars
About
Editions
Webinars
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024